Weight Loss Drugs Ozempic and Wegovy: Same Molecule, Different Licences

Ozempic and Wegovy use the same drug, so why does the licence difference matter?

Semaglutide was developed by Novo Nordisk first as a diabetes treatment and later studied at higher doses specifically for weight management. The result was two separate products: Ozempic (approved for type 2 diabetes) and Wegovy (approved for obesity and weight-related conditions). The active molecule is identical; what differs is the licensed dose, the clinical indication, and the evidence base that sits behind each approval.

In the UK, the NHS semaglutide medicines page makes the split clear: Wegovy is the weight-management form, Ozempic is not. The MHRA evaluates medicines for specific indications, and Ozempic has not been assessed for weight loss in the way Wegovy has. That means a UK prescriber issuing Ozempic for weight loss would be acting outside the product's licence, which is a different clinical and regulatory position from prescribing Wegovy, where the evidence and the licence align.

This is a question our prescribers hear most weeks: people who have read about using semaglutide or Ozempic for weight loss and wonder whether they can get it for weight management. The short answer is that Wegovy is the appropriate licensed route, and it is the version that has been through full MHRA scrutiny for that purpose.

What does Wegovy actually do, and what did the trials show?

Semaglutide works as a GLP-1 receptor agonist. It mimics a gut hormone released after eating, slowing gastric emptying, reducing appetite and helping the body regulate food intake. At the 2.4mg weekly dose used in Wegovy, this effect is more pronounced than at the lower doses in the diabetes licence.

The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. Participants using semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight, compared with around 2.4% in the placebo group. These are meaningful figures, though worth noting they represent averages from a clinical trial, and individual results vary depending on diet, activity, starting weight and other factors.

More recently, the MHRA approved a higher 7.2mg maintenance dose for Wegovy, with a dedicated single-dose pen approved in April 2026. Trial data for this higher dose reported average weight loss of around 20.7% over 72 weeks. If you want to understand how the Wegovy evidence compares with tirzepatide, the comparison of Wegovy with other weight loss drugs covers that in more detail.

Who is Wegovy licensed for, and what are the eligibility thresholds?

Wegovy's UK licence covers adults with a BMI of 30 or above, and those with a BMI of 27 to 29.9 who have at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Pregnancy, breastfeeding and trying to conceive are situations where Wegovy is not recommended; the same applies to those under 18.

NICE has also issued a technology appraisal for Wegovy on the NHS, under TA875, which recommends it for a maximum of two years within specialist weight management services and with stricter BMI thresholds than the private licence. NHS waiting lists for those services can be long, which is one reason people look at private options.

Tirzepatide, sold as Mounjaro, is an alternative licensed for the same BMI ranges in the UK and works on both GLP-1 and GIP receptors. Details on how the two medicines sit alongside each other are on the semaglutide overview page. The clearest way to know which treatment suits your situation is a clinical assessment rather than a comparison article.

Ozempic and weight loss: what if your GP has mentioned it?

There is a separate, nuanced scenario: a person with type 2 diabetes who is also carrying excess weight and whose GP has prescribed Ozempic primarily for blood-sugar control. If weight loss follows as a secondary outcome, that is not the same as seeking Ozempic specifically as a weight-loss drug. The prescriber in that case is working within the licensed indication for diabetes, and any weight benefit is a recognised secondary effect.

For people without type 2 diabetes who are searching for weight management treatment, Ozempic is not the right route, and our page explaining whether Wegovy and Ozempic are the same thing sets out the distinction in plain terms. So is Mounjaro, which you can explore through the weight loss drugs similar to Wegovy page. Cost is a factor for many people considering private treatment, and understanding how Wegovy pricing works is worth doing before you start, the Wegovy weight loss treatment page sets out what a legitimate private prescription includes.

If you are ready to find out whether Wegovy is clinically appropriate for you, starting a free consultation with one of our GPhC-registered prescribers is the place to begin. Every consultation is reviewed personally, the same day.